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EDITORIAL COMMENT
Matrix Metalloproteinases
and Atrial Structural Remodeling*
Brian D. Hoit, MD, FACC
Cleveland, Ohio
Atrial fibrillation (AF) is a common arrhythmia, affecting
approximately 5% of the population older than 65 years; the
arrhythmia is associated with significant morbidity and
mortality, and it is challenging and often frustrating to treat
(1,2). There is a tendency for AF to become chronic and
more resistant to cardioversion with increasing duration of
the arrhythmia (3). Although the details are poorly under-
stood, persistence of AF is thought to result from the atrial
remodeling that occurs.
ATRIAL REMODELING
Remodeling of the atrium may refer to changes in structure
and function (structural or mechanical remodeling) or elec-
trophysiologic properties (electrical remodeling; ionic and
gap junction remodeling) that occur in response to a
pathologic stimulus (most commonly, rapid atrial or ven-
tricular pacing). Because of the disparities in the time course
of tachycardia-induced electrical remodeling and recovery of
atrial function (4,5), it is likely that structural (and not
electrical) remodeling is responsible for the substrate that
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favors AF persistence and the prevention of AF by prompt
cardioversion. However, whether structural remodeling is
simply a marker for the electrophysiologic changes, or is in
some way causal, or is important only for final stabilization
of the arrhythmia remains uncertain.
Atrial fibrosis has been demonstrated to provide a mor-
phological substrate for AF both in the setting of left
ventricular (LV) dysfunction and in mitral valvular disease
(6,7). Unlike the atrial remodeling associated with rapid
atrial pacing, which promotes AF maintenance by reducing
the wavelength for reentry and increasing the regional
disparity of refractoriness, rapid ventricular pacing alters the
heterogeneity of conduction velocity and is associated with
interstitial fibrosis, increased atrial angiotensin II levels, and
prolonged episodes of AF (6,8). Moreover, treatment with
an angiotensin-converting enzyme (ACE) inhibitor reduces
the duration of AF and attenuates the structural remodeling
seen in this model; these data are consistent with the
reduced relapse rate of AF after cardioversion in patients
pretreated with lisinopril (9), and the increased incidence of
AF in control versus trandolapril-treated patients in the
TRACE study (10). Novel genetic models of AF in the
mouse provide further insights (11,12); for example,
connexin-40 knockout mice have slower atrial conduction
velocity compared to wild-type mice and increased vulner-
ability to atrial arrhythmia (11), and constitutive TGF-
overexpression produces increased atrial fibrosis and epi-
sodes of inducible AF (12). In addition to their contribu-
tions to understanding the pathophysiology of AF, these
data and others in murine models challenge the hypothesis
that a critical atrial mass is necessary for the maintenance of
AF (13).
FIBROSIS OF THE LEFT ATRIUM DURING
PROGRESSION OF HEART FAILURE IN THE RAT
In this context, the report by Boixel et al. (14) in this issue
of the Journal is of particular interest. Twelve weeks after
LV infarction in rats, dilation, interstitial fibrosis, and
altered expression of matrix metalloproteinases (MMPs)
were noted in the left atrium. Animals with “severe” heart
failure (increased heart weight, right ventricular weight, and
left atrial weight-to-body-weight ratios, increased plasma
ANP [atrial natriuretic peptide], and urinary cGMP
[guanosine 35-cyclic monophosphate]), had increased ex-
pression of MMP-7 and MMP-2 localized to myocytes and
the interstitial space, respectively; MMP-7 alone was in-
creased in animals with severe heart failure. Increases in
MMP-13, the major rodent interstitial collagenase, were
not statistically significant in either group, and there were
no differences in the protein expression of endogenous tissue
inhibitors of matrix metalloproteinases (TIMPs). Fibrosis
was present in both compensated and decompensated in-
farctions. However, these structural changes were unaccom-
panied by atrial arrhythmia, either supporting the conten-
tion that structural changes precede and are in some fashion
causal in, or that the milieu and size of the atrium (critical
mass hypothesis) are insufficient for, the maintenance of
AF. A linear relation between the amount of atrial fibrosis
in right atrial appendages taken at the time of open-heart
surgery and the incidence of postoperative AF was recently
demonstrated (15). Unfortunately, in the study by Boixel et
al. (14), fibrosis was not quantified.
An apparent paradox is that an increase in MMP activity
induced fibrosis, whereas a decrease in the amount of
collagen might have been expected. This is because the total
matrix collagen content is a function of both synthesis and
degradation, and degraded products of matrix proteins serve
as a stimulus for collagen synthesis; this in turn may result
in increased deposition of poorly structured fibrotic tissue
(16). Therefore, the MMPs result in collagen deposition
and denaturation, and hence a change in both the content
and quality of collagen.
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MMPs AND ATRIAL REMODELING
Matrix metalloproteinases (MMPs) comprise a large mul-
tigene family of structurally and functionally homologous
neutral proteinases that play a critically important role in
extracellular matrix turnover and are implicated in the
pathogenesis of a variety of cardiovascular disease (17). The
MMPs consist of three highly conserved domains: an
amino-terminal propeptide, a catalytic domain containing
zinc and calcium ions, and a hemopexin-like domain at the
carboxy-terminal, which binds substrate and interacts with
the endogenous tissue inhibitors of MMPs (TIMPs) (18).
The MMPs are secreted by fibroblasts, smooth muscle cells,
endothelial cells, and myocytes as inactive zymogens, re-
quiring cleavage of the pro-peptide by proteolysis for acti-
vation. The MMPs are classified according to substrate
specificity (although several MMPs can degrade a number
of matrix components) and domain organization, and they
classically are subdivided into the interstitial collagenases
(MMP-1, MMP-8, MMP-13), the gelatinases (MMP-2,
MMP-9), the stromelysins (MMP-3, MMP-10), and an
unclassified group (membrane-type, MMP-7, MMP-11,
MMP-12). Regulation of MMPs is complex and occurs by
gene transcription, protein activation, and inhibition by one
of four TIMPs.
Activation of MMPs and disruption of the collagen struts
and fibers are proposed to play important roles in subse-
quent cell slippage, eccentric hypertrophy, and changes in
ventricular geometry after myocardial infarction (MI) and
remodeling of the left ventricle in cardiomyopathy (19–22).
Although there is rapidly accumulating data with respect to
the role of MMPs in ventricular remodeling, aside from the
study by Boixel et al. (14), there are few published data
existing for the atrium. Recent data from our laboratory
suggest that activation of MMPs is responsible for the
structural remodeling of the left atrium in response to rapid
atrial pacing (23). In that study, left atrial myocardium was
examined from dogs with rapid pacing-induced atrial failure
(400 beats/min for 6 weeks) and from control dogs. Acti-
vation of MMPs was measured using gelatin and casein
zymography, and levels of the cardiospecific tissue inhibitor
of metalloproteinase-4 (TIMP-4) and the TIMP-4/MMP
complex were measured with Western blot analysis. In
contrast to the study by Boixel et al., the activity of MMP-9
was selectively and significantly increased by50%, and the
level of complexed TIMP-4 protein was significantly de-
creased by 50% in samples from dogs with atrial failure.
Differences in species and experimental models may be
responsible for the disparate findings.
The ADAMs (a disintegrin and metalloproteinase) are
transmembrane proteins that function (largely in unknown
fashion) in a wide variety of biological processes (24).
Although collagen degradation provides new integrin-
binding sites that are necessary for cell survival, a complete
loss of integrin signaling due to detachment from the
extracellular matrix results in apoptosis, dilation, and fail-
ure—all features of the remodeling process (25,26). We
recently identified increased levels of an ADAM and de-
creased levels of TIMP-4 in human heart end-stage failure
(27). In addition, expressions of ADAM10 and ADAM15
were increased in atrial tissue from patients with chronic
AF, and ADAM expression was correlated with the
amounts of integrins 1 and 3 (28). These early data
suggest that ADAMs may also be involved in the patho-
genesis of atrial remodeling and fibrillation.
CAUTIONARY NOTES
Boixel et al. (14) suggest that atrial fibrosis results from
hemodynamic loading, but in their model the roles of local
and systemic neurohormonal stimuli, such as angiotensin II,
bradykinin, and endothelin, remain uncertain. The renin-
angiotensin system is considered to be important in produc-
ing the fibrotic changes that comprise structural remodeling
(29). In addition, increased systemic aldosterone levels are
noted in failing ventricles and in patients with AF (30,31),
and may contribute to the atrial fibrosis in this model. It is
also important to remember that remodeling involves many
processes, and it is influenced not only by hemodynamic
load, wall stresses, and neurohormonal activation, but also
by apoptosis and changes in cytokines, nitric oxide produc-
tion, and oxidative stress (32).
Remodeling is also a dynamic process, and activation of
MMPs, like apoptosis, is time-dependent; however, in the
study by Boixel et al. (14), MMPs and TIMPs were assessed
only at a single time point. Moreover, MMPs are differen-
tially activated and expressed according to the nature of the
loading stimulus (e.g., pressure vs. volume overload) and the
temporal profile (e.g., acute vs. chronic) (33). For example,
in the rat, MMP/TIMP regulation evolves differentially
during the 16 weeks after infarction; MMP-13 predomi-
nates in the early postischemic period, whereas MMP-14
increases during later remodeling. Protein levels of MMP-2,
-9, -13, and -14 are post-transcriptionally increased in the
ventricle. Although the time course of collagenolytic activity
after MI suggests a correlation between such activity,
ventricular remodeling, and systolic function (19), the de-
tails of the time course of atrial mechanical remodeling are
not as well characterized, and these may have important
implications for the termination of AF, atrial stunning after
cardioversion, and the maintenance of sinus rhythm.
Conspicuously absent in the study by Boixel et al. (14) is
an assessment of left atrial function, admittedly a daunting
task in rodents. The cardiac interstitium and its fibrillar
collagen matrix play a critical role in determining cardiac
performance (34). Cardiac collagen maintains the structural
integrity and overall geometry of the heart; but in addition,
the extracellular matrix tethers and aligns individual myo-
cytes and myofibrils, enabling optimal transduction and
coordination of force generated during cardiac contraction.
Although the mechanism is not clear, matrix alterations
may produce an added hemodynamic stress, or may disturb
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signaling between myocytes. The MMP activation may be
linked to mechanical dysfunction in an additional manner:
in situ zymography of explanted cardiomyopathic hearts
demonstrated that gelatinases (MMP-2 and -9) were phys-
ically associated with the sarcomeres; and, in vitro, myosin
heavy chain was digested by the gelatinases (35).
Conclusions. The MMPs can be regarded as potential
etiologic agents in atrial remodeling for several reasons.
First, there is biologic plausibility; the extracellular matrix is
physically and biochemically in close communication with
the cytoskeleton (e.g., 1 integrins). Second, defects in the
dystrophin-dystroglycan-laminin complex produce dilated
cardiomyopathy. Finally, and most convincingly, studies
with MMP inhibitors in animal models and genetically
engineered mice demonstrate salutary effects of MMPs on
the course of cardiac dilation and heart failure (20,36–38).
We wholeheartedly agree with Boixel et al. that studies with
specific MMP inhibition in well-defined models of AF and
structural remodeling are warranted.
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